Morphosys in Transformative Deal With Celgene, Morphs Into FIBCO
This article was originally published in The Pink Sheet Daily
Morphosys and Celgene have agreed to jointly develop MOR202 for multiple myeloma, and to co-promote it in Europe. The deal allows Morphosys for the first time to participate in the commercialization of one of its products and decisively validates commercial interest in one of the industry’s hot oncology targets
You may also be interested in...
The British pharma is expanding its portfolio in rheumatoid arthritis through a mid-stage tie-up with German biotech MorphoSys. GSK will take over all development of the antibody and could pay milestones up to €425 million.
Celgene Corp. has deepened its investment in antibody R&D, striking a collaboration with Sutro Biopharma to design and develop next-gen antibodies and to manufacture a proprietary Celgene candidate. Sutro gets cash, biobucks, and hi-profile validation of its multi-faceted non-cell antibody platform.
MorphoSys sells some of its assets in an effort to concentrate on its proprietary therapeutic endeavors – including a mid-stage rheumatoid arthritis drug.